March 2007 Oncology News International

Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.